Stayble Therapeutics AB (STU:4K4) Change In Receivables : €-0.10 Mil (TTM As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB Change In Receivables?

Stayble Therapeutics AB's change in receivables for the quarter that ended in Sep. 2023 was €0.05 Mil. It means Stayble Therapeutics AB's Accounts Receivable declined by €0.05 Mil from Jun. 2023 to Sep. 2023 .

Stayble Therapeutics AB's change in receivables for the fiscal year that ended in Dec. 2022 was €-0.01 Mil. It means Stayble Therapeutics AB's Accounts Receivable increased by €0.01 Mil from Dec. 2021 to Dec. 2022 .

Stayble Therapeutics AB's Accounts Receivable for the quarter that ended in Sep. 2023 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Stayble Therapeutics AB's liquidation value for the three months ended in Sep. 2023 was €1.27 Mil.

Stayble Therapeutics AB Change In Receivables Historical Data

The historical data trend for Stayble Therapeutics AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Change In Receivables Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

0.01

-0.12

0.09

-0.01

Stayble Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Receivables	Get a 7-Day Free Trial															-0.04	0.04	-0.33	0.13	0.05

Stayble Therapeutics AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.10 Mil.

Stayble Therapeutics AB (STU:4K4) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Stayble Therapeutics AB's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Stayble Therapeutics AB's accounts receivable are only considered to be worth 75% of book value:

Stayble Therapeutics AB's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.8	-	0.535	+	0.75 * 0	+	0.5 * 0
=	1.27

Stayble Therapeutics AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (STU:4K4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

STABL:Sweden 4K4:Germany

Address

Medicinaregatan 8a, Gothenburg, SWE, SE-413 90

Website

http://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (STU:4K4) Headlines

No Headlines